203 research outputs found
Comparison of two- and three-dimensional simulations of miscible Rayleigh-Taylor instability
A comparison of two-dimensional and three-dimensional high-resolution numerical large-eddy simulations of planar, miscible Rayleigh-Taylor instability flows are presented. The resolution of the three-dimensional simulation is sufficient to attain a fully turbulent state. A number of different statistics from the mixing region (e.g., growth rates, PDFs, mixedness measures, and spectra) are used to demonstrate that two-dimensional flow simulations differ substantially from the three-dimensional one. It is found that the two-dimensional flow grows more quickly than its three-dimensional counterpart at late times, develops larger structures, and is much less well mixed. These findings are consistent with the concept of inverse cascade in two-dimensional flow, as well as the influence of a reduced effective Atwood number on miscible flow
BCG-INDUCED PRO-INFLAMMATORY PHENOTYPE OF MESENCHYMAL STEM CELLS: EFFECT OF IMMUNE MODULATORS
In case of mycobacterial infection the granulomatous infiltration foci contain the significant amount of mesenchymal stem cells (MSC), which functional phenotype and respective function in anti-tuberculosis immune defense remain unknown.Goal of the study: to characterize the MSC phenotype, formed by their interaction with BCG of M. bovis and to evaluate the changes in this phenotype caused by the action of inhibitors and stimulants of immune regulatory action.Materials and methods: MSC retrieved from bone marrow of mice were cultured with the presence and absence of BCG of M. bovis and/or poludanum TLR3 agonist; and the effect of two latter on the production of pro- and anti-inflammatory cytokines was evaluated by enzyme multiplied immunoassay. Flow cytometry and radioactive testing were used to evaluate the impact of cultured BCG fluid and poludanum-conditioned MSC on the proliferative and apoptotic activity of splenocytes. The inhibitors of indoleamine 2,3-dioxygenase (IDO), cyclooxygenase-2 (COG-2) or NO synthase were added to certain cultures alone with BCG and poludanum, and the contributions of IDO, COG-2 and NO to BCG and poludanum-induced response were assessed.Results. Pro-inflammatory polarization of MSC under the action of BCG and poludanum was demonstrated. Pro-inflammatory MSC phenotype correlated to their anti-apoptogenic and growth-stimulating actions on the splenocytes. It was demonstrated that IDO and NO restrained BCG-induced polarization and conversely COG-2 promoted BCG-induced pro-inflammatory polarization of MSC.Conclusions. 1. MSC actively participate in the formation of immunologic anti-mycobacterial resistance. 2. Targeted regulation of IDO and NO production can be feasibly applied for formation of anti-tuberculous vaccinal immunity and control mycobacterial infection
Comparison of two- and three-dimensional simulations of miscible Rayleigh-Taylor instability
ΠΠ¦Π-ΠΠΠΠ£Π¦ΠΠ ΠΠΠΠΠΠ«Π ΠΠ ΠΠΠΠ‘ΠΠΠΠΠ’ΠΠΠ¬ΠΠ«Π Π€ΠΠΠΠ’ΠΠ ΠΠΠΠΠΠ₯ΠΠΠΠΠ¬ΠΠ«Π₯ Π‘Π’ΠΠΠΠΠΠ«Π₯ ΠΠΠΠ’ΠΠ: ΠΠΠΠ―ΠΠΠ ΠΠΠΠ£ΠΠΠΠΠΠ£ΠΠ―Π’ΠΠ ΠΠ
In case of mycobacterial infection the granulomatous infiltration foci contain the significant amount of mesenchymal stem cells (MSC), which functional phenotype and respective function in anti-tuberculosis immune defense remain unknown.Goal of the study: to characterize the MSC phenotype, formed by their interaction with BCG of M. bovis and to evaluate the changes in this phenotype caused by the action of inhibitors and stimulants of immune regulatory action.Materials and methods: MSC retrieved from bone marrow of mice were cultured with the presence and absence of BCG of M. bovis and/or poludanum TLR3 agonist; and the effect of two latter on the production of pro- and anti-inflammatory cytokines was evaluated by enzyme multiplied immunoassay. Flow cytometry and radioactive testing were used to evaluate the impact of cultured BCG fluid and poludanum-conditioned MSC on the proliferative and apoptotic activity of splenocytes. The inhibitors of indoleamine 2,3-dioxygenase (IDO), cyclooxygenase-2 (COG-2) or NO synthase were added to certain cultures alone with BCG and poludanum, and the contributions of IDO, COG-2 and NO to BCG and poludanum-induced response were assessed.Results. Pro-inflammatory polarization of MSC under the action of BCG and poludanum was demonstrated. Pro-inflammatory MSC phenotype correlated to their anti-apoptogenic and growth-stimulating actions on the splenocytes. It was demonstrated that IDO and NO restrained BCG-induced polarization and conversely COG-2 promoted BCG-induced pro-inflammatory polarization of MSC.Conclusions. 1. MSC actively participate in the formation of immunologic anti-mycobacterial resistance. 2. Targeted regulation of IDO and NO production can be feasibly applied for formation of anti-tuberculous vaccinal immunity and control mycobacterial infection.Β ΠΡΠΈ ΠΌΠΈΠΊΠΎΠ±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π² ΠΎΡΠ°Π³Π°Ρ
Π³ΡΠ°Π½ΡΠ»Π΅ΠΌΠ°ΡΠΎΠ·Π½ΠΎΠΉ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠΈ ΡΠΎΠ΄Π΅ΡΠΆΠΈΡΡΡ Π±ΠΎΠ»ΡΡΠΎΠ΅ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΌΠ΅Π·Π΅Π½Ρ
ΠΈΠΌΠ°Π»ΡΠ½ΡΡ
ΡΡΠ²ΠΎΠ»ΠΎΠ²ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ (ΠΠ‘Π), ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΉ ΡΠ΅Π½ΠΎΡΠΈΠΏ ΠΊΠΎΡΠΎΡΡΡ
ΠΈ, ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ, ΡΡΠ½ΠΊΡΠΈΡ Π² ΠΏΡΠΎΡΠΈΠ²ΠΎΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·Π½ΠΎΠΌ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ΅ Π½Π΅ΠΈΠ·Π²Π΅ΡΡΠ½Ρ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΠΎΡ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΎΠ²Π°ΡΡ ΡΠ΅Π½ΠΎΡΠΈΠΏ ΠΠ‘Π, ΡΠΎΡΠΌΠΈΡΡΡΡΠΈΠΉΡΡ ΠΏΡΠΈ ΠΈΡ
Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠΈ Ρ M. bovis ΠΠ¦Π, ΠΈ ΠΎΡΠ΅Π½ΠΈΡΡ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΡΠΎΠ³ΠΎ ΡΠ΅Π½ΠΎΡΠΈΠΏΠ° ΠΏΠΎΠ΄ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ΠΌ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² ΠΈ ΡΡΠΈΠΌΡΠ»ΡΡΠΎΡΠΎΠ² ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π³ΡΠ»ΡΡΠΎΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: ΠΠ‘Π, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΠΈΠ· ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° ΠΌΡΡΠ΅ΠΉ, ΠΊΡΠ»ΡΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π»ΠΈ Π² ΠΏΡΠΈΡΡΡΡΡΠ²ΠΈΠΈ ΠΈΠ»ΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠΈ M. bovis ΠΠ¦Π ΠΈ/ΠΈΠ»ΠΈ Π°Π³ΠΎΠ½ΠΈΡΡΠ° TLR3 ΠΏΠΎΠ»ΡΠ΄Π°Π½Π° ΠΈ ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΡ
Π½Π° ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡ ΠΏΡΠΎ- ΠΈ Π°Π½ΡΠΈΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ². ΠΠ΅ΡΠΎΠ΄Π°ΠΌΠΈ ΠΏΡΠΎΡΠΎΡΠ½ΠΎΠΉ ΡΠΈΡΠΎΠΌΠ΅ΡΡΠΈΠΈ ΠΈ ΡΠ°Π΄ΠΈΠΎΠ°ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΊΡΠ»ΡΡΡΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠΈ ΠΠ¦Π- ΠΈ ΠΏΠΎΠ»ΡΠ΄Π°Π½-ΠΊΠΎΠ½Π΄ΠΈΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΠ‘Π Π½Π° ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠ²Π½ΡΡ ΠΈ Π°ΠΏΠΎΠΏΡΠΎΡΠΈΡΠ΅ΡΠΊΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠΏΠ»Π΅Π½ΠΎΡΠΈΡΠΎΠ². Π ΡΠ°ΡΡΡ ΠΊΡΠ»ΡΡΡΡ Π²ΠΌΠ΅ΡΡΠ΅ Ρ ΠΠ¦Π ΠΈΠ»ΠΈ ΠΏΠΎΠ»ΡΠ΄Π°Π½ΠΎΠΌ Π΄ΠΎΠ±Π°Π²Π»ΡΠ»ΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ ΠΈΠ½Π΄ΠΎΠ»Π°ΠΌΠΈΠ½-2,3-Π΄ΠΈΠΎΠΊΡΠΈΠ³Π΅Π½Π°Π·Ρ (ΠΠΠ), ΡΠΈΠΊΠ»ΠΎΠΎΠΊΡΠΈΠ³Π΅Π½Π°Π·Ρ-2 (Π¦ΠΠ-2) ΠΈΠ»ΠΈ NO ΡΠΈΠ½ΡΠ°Π·Ρ ΠΈ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ Π²ΠΊΠ»Π°Π΄ ΠΠΠ, Π¦ΠΠ-2 ΠΈ NO Π² ΠΠ¦Π- ΠΈ ΠΏΠΎΠ»ΡΠ΄Π°Π½-ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ ΠΎΡΠ²Π΅Ρ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎΠΊΠ°Π·Π°Π½Π° ΠΏΡΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΠΏΠΎΠ»ΡΡΠΈΠ·Π°ΡΠΈΡ ΠΠ‘Π ΠΏΠΎΠ΄ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ΠΌ ΠΠ¦Π ΠΈ ΠΏΠΎΠ»ΡΠ΄Π°Π½Π°. ΠΡΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΠ΅Π½ΠΎΡΠΈΠΏ ΠΠ‘Π ΠΊΠΎΡΡΠ΅Π»ΠΈΡΠΎΠ²Π°Π» Ρ ΠΈΡ
Π°Π½ΡΠΈΠ°ΠΏΠΎΠΏΡΠΎΠ³Π΅Π½Π½ΠΎΠΉ ΠΈ ΡΠΎΡΡΠΎΡΡΠΈΠΌΡΠ»ΠΈΡΡΡΡΠ΅ΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ ΠΏΠΎ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΠΊ ΡΠΏΠ»Π΅Π½ΠΎΡΠΈΡΠ°ΠΌ. ΠΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ, ΡΡΠΎ ΠΠΠ ΠΈ NO ΡΠ΄Π΅ΡΠΆΠΈΠ²Π°ΡΡ ΠΠ¦Π-ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ ΠΏΠΎΠ»ΡΡΠΈΠ·Π°ΡΠΈΡ, Π° Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π¦ΠΠ-2, Π½Π°ΠΎΠ±ΠΎΡΠΎΡ, ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΡΠ΅Ρ ΠΠ¦Π-ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΏΡΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΏΠΎΠ»ΡΡΠΈΠ·Π°ΡΠΈΠΈ ΠΠ‘Π.ΠΡΠ²ΠΎΠ΄Ρ. 1. ΠΠ‘Π ΡΠ²Π»ΡΡΡΡΡ Π°ΠΊΡΠΈΠ²Π½ΡΠΌΠΈ ΡΡΠ°ΡΡΠ½ΠΈΠΊΠΈ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°Π½ΡΠΈΠΌΠΈΠΊΠΎΠ±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ. 2. Π’Π°ΡΠ³Π΅ΡΠ½ΠΎΠ΅ ΡΠ΅Π³ΡΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠΈ ΠΠΠ ΠΈ ΠΎΠΊΡΠΈΠ΄Π° Π°Π·ΠΎΡΠ° ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΡΠ΅Π»Π΅ΡΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎ Π΄Π»Ρ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·Π½ΠΎΠ³ΠΎ Π²Π°ΠΊΡΠΈΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ° ΠΈ Π΄Π»Ρ Π±ΠΎΡΡΠ±Ρ Ρ ΠΌΠΈΠΊΠΎΠ±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial
IMPORTANCE: Secretory phospholipase A2(sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. OBJECTIVE: To determine the effects of sPLA2inhibition with varespladib on cardiovascular outcomes. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n = 2572) or placebo (n = 2573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). INTERVENTIONS: Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. MAIN OUTCOMES AND MEASURES: The primary efficacy measurewas a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. RESULTS: At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95%CI, 0.97-1.61; log-rank P = .08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95%CI, 1.16-2.39; log-rank P = .005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P = .04). CONCLUSIONS AND RELEVANCE: In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01130246. Copyright 2014 American Medical Association. All rights reserved
ΠΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π²Π°ΡΠΈΠ°Π½ΡΡ Π΄Π΅Π±ΡΡΠ° Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠ² ΠΏΡΠΈ Π²ΡΠΎΠΆΠ΄ΡΠ½Π½ΠΎΠΉ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΈ Π³Π΅ΠΏΠ°ΡΠΈΡΠ΅ Π‘
We present comparative analysis of clinical βΒ morphological data from infants with congenital cytomegalovirusΒ and hepatitis C infection. 97 patients with hepatitis underwentΒ a standard set of clinical and laboratory tests. ELISAΒ and PCR were used to verify infectious agents. Informed consentΒ to perform a liver biopsy was obtained from the parentsΒ of 28 children. immunohistochemical test of the liver samplesΒ managed to identify markers of cytomegalovirus (proteinΒ pp65 and p52) and hepatitis C (helicase NS3). The hepatitis CΒ virus was detected in 41 patients: 3a genotype β 68.3%, 1b β31.7% respectively. Congenital hepatitis C onset presentsΒ itself as mild and atypical and causes chronic hepatitis withΒ the 1st degree fibrosis. Cytomegalovirus replication markersΒ were found in 56 children. The most common manifestationsΒ of hepatitis associated with cytomegalovirus infection areΒ prolonged jaundice, cholestasis, gepatolienalny syndrome,Β early onset of the disease with increased transaminase levelsΒ and dominance in AST. Structural changes of the liver areΒ characterized by the presence of inflammatory infiltration,Β cholestasis with duktulopenia, lobular structure damage.Β Congenital cytomegalovirus-related hepatitis is likely to resultΒ in liver cirrhosis and is associated with poor prognosis.ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ·Β ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π΄Π°Π½Π½ΡΡ
Ρ Π΄Π΅ΡΠ΅ΠΉ ΠΏΠ΅ΡΠ²ΠΎΠ³ΠΎ Π³ΠΎΠ΄Π°Β ΠΆΠΈΠ·Π½ΠΈ Ρ Π²ΡΠΎΠΆΠ΄Π΅Π½Π½ΡΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌ Π‘ ΠΈ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ. Π£ 97 Π±ΠΎΠ»ΡΠ½ΡΡ
Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ½Β ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΡΠΉ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
Β ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, Π²Π΅ΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΡΡ
Π°Π³Π΅Π½ΡΠΎΠ² ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌΠΈ ΠΠ€Π ΠΈ ΠΠ¦Π -Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ. Π Π°Π·ΡΠ΅ΡΠ΅Π½ΠΈΠ΅Β Π½Π° ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ Π±ΠΈΠΎΠΏΡΠΈΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΎ Ρ ΡΠΎΠ΄ΠΈΡΠ΅Π»Π΅ΠΉΒ 28 Π΄Π΅ΡΠ΅ΠΉ. Π Π³Π΅ΠΏΠ°ΡΠΎΠ±ΠΈΠΎΠΏΡΠ°ΡΠ°Ρ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΠΈ ΠΈΠ΄Π΅Π½ΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Ρ ΠΌΠ°ΡΠΊΡΡΡ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ (Π±Π΅Π»ΠΎΠΊ pp65 ΠΈ p52) ΠΈ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘ (Ρ
Π΅Π»ΠΈΠΊΠ°Π·Π°Β NS3). ΠΠΈΡΡΡ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘ Π²ΡΡΠ²Π»Π΅Π½ Ρ 41 ΡΠ΅Π±ΡΠ½ΠΊΠ°: 3Π° Π³Π΅Π½ΠΎΡΠΈΠΏ β 68,3%, 1Π² β 31,7%. ΠΡΠΎΠΆΠ΄ΡΠ½Π½ΡΠΉ Π³Π΅ΠΏΠ°ΡΠΈΡ Π‘ Π΄Π΅Π±ΡΡΠΈΡΡΠ΅Ρ Π² Π°ΡΠΈΠΏΠΈΡΠ½ΠΎΠΉ Π»ΡΠ³ΠΊΠΎΠΉ ΡΠΎΡΠΌΠ΅ ΠΈ ΡΠΎΡΠΌΠΈΡΡΠ΅Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ Π³Π΅ΠΏΠ°ΡΠΈΡ Ρ ΡΠΈΠ±ΡΠΎΠ·ΠΎΠΌ 1 ΡΡΠ΅ΠΏΠ΅Π½ΠΈ. ΠΠ°ΡΠΊΡΡΡ ΡΠ΅ΠΏΠ»ΠΈΠΊΠ°ΡΠΈΠΈ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ° ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Ρ Ρ 56 Π΄Π΅ΡΠ΅ΠΉ. Β«ΠΠΈΠ·ΠΈΡΠ½ΠΎΠΉ ΠΊΠ°ΡΡΠΎΡΠΊΠΎΠΉΒ» Π³Π΅ΠΏΠ°ΡΠΈΡΠ° ΠΏΡΠΈ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉΒ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ Π·Π°ΡΡΠΆΠ½Π°Ρ ΠΆΠ΅Π»ΡΡΡ
Π°, Ρ
ΠΎΠ»Π΅ΡΡΠ°Π·, Π³Π΅ΠΏΠ°ΡΠΎΠ»ΠΈΠ΅Π½Π°Π»ΡΠ½ΡΠΉ ΡΠΈΠ½Π΄ΡΠΎΠΌ, ΡΠ°Π½Π½ΠΈΠΉ Π΄Π΅Π±ΡΡ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΡΠΎΠ²Π½Ρ ΡΡΠ°Π½ΡΠ°ΠΌΠΈΠ½Π°Π· ΠΈ Π΄ΠΎΠΌΠΈΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΡΠΎΠ²Π½ΡΒ ΠΡΠΠ’. Π‘ΡΡΡΠΊΡΡΡΠ½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΡΡ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠΈ, Ρ
ΠΎΠ»Π΅ΡΡΠ°Π·Π°Β Ρ ΠΏΡΠΈΠ·Π½Π°ΠΊΠ°ΠΌΠΈ Π΄ΡΠΊΡΡΠ»ΠΎΠΏΠ΅Π½ΠΈΠΈ, Π½Π°ΡΡΡΠ΅Π½ΠΈΠ΅ΠΌ Π΄ΠΎΠ»ΡΠΊΠΎΠ²ΠΎΠ³ΠΎΒ ΡΡΡΠΎΠ΅Π½ΠΈΡ. ΠΡΠΈ Π²ΡΠΎΠΆΠ΄ΡΠ½Π½ΠΎΠΌ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠ΅ Π²ΡΡΠΎΠΊΠ° Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΡ ΠΈΡΡ
ΠΎΠ΄Π° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π² ΡΠΈΡΡΠΎΠ·Β ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΈ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΉ ΠΏΡΠΎΠ³Π½ΠΎΠ·
Eradication of Metastatic Renal Cell Carcinoma after Adenovirus-Encoded TNF-Related Apoptosis-Inducing Ligand (TRAIL)/CpG Immunotherapy
Despite evidence that antitumor immunity can be protective against renal cell carcinoma (RCC), few patients respond objectively to immunotherapy and the disease is fatal once metastases develop. We asked to what extent combinatorial immunotherapy with Adenovirus-encoded murine TNF-related apoptosis-inducing ligand (Ad5mTRAIL) plus CpG oligonucleotide, given at the primary tumor site, would prove efficacious against metastatic murine RCC. To quantitate primary renal and metastatic tumor growth in mice, we developed a luciferase-expressing Renca cell line, and monitored tumor burdens via bioluminescent imaging. Orthotopic tumor challenge gave rise to aggressive primary tumors and lung metastases that were detectable by day 7. Intra-renal administration of Ad5mTRAIL+CpG on day 7 led to an influx of effector phenotype CD4 and CD8 T cells into the kidney by day 12 and regression of established primary renal tumors. Intra-renal immunotherapy also led to systemic immune responses characterized by splenomegaly, elevated serum IgG levels, increased CD4 and CD8 T cell infiltration into the lungs, and elimination of metastatic lung tumors. Tumor regression was primarily dependent upon CD8 T cells and resulted in prolonged survival of treated mice. Thus, local administration of Ad5mTRAIL+CpG at the primary tumor site can initiate CD8-dependent systemic immunity that is sufficient to cause regression of metastatic lung tumors. A similar approach may prove beneficial for patients with metastatic RCC
Phase transition in Random Circuit Sampling
Quantum computers hold the promise of executing tasks beyond the capability
of classical computers. Noise competes with coherent evolution and destroys
long-range correlations, making it an outstanding challenge to fully leverage
the computation power of near-term quantum processors. We report Random Circuit
Sampling (RCS) experiments where we identify distinct phases driven by the
interplay between quantum dynamics and noise. Using cross-entropy benchmarking,
we observe phase boundaries which can define the computational complexity of
noisy quantum evolution. We conclude by presenting an RCS experiment with 70
qubits at 24 cycles. We estimate the computational cost against improved
classical methods and demonstrate that our experiment is beyond the
capabilities of existing classical supercomputers
Recommended from our members
Two Dimensional Simulations of Plastic-Shell, Direct-Drive Implosions on OMEGA
Multidimensional hydrodynamic properties of high-adiabat direct-drive plastic-shell implosions on the OMEGA laser system [T. R. Boehly et al., Opt. Commun. 133, 495 (1997)] are investigated using the multidimensional hydrodynamic code, DRACO. Multimode simulations including the effects of nonuniform illumination and target roughness indicate that shell stability during the acceleration phase plays a critical role in determining target performance. For thick shells that remain integral during the acceleration phase, target yields are significantly reduced by the combination of the long-wavelength ({ell} < 10) modes due to surface roughness and beam imbalance and the intermediate modes (20 {le} {ell} {le} 50) due to single-beam nonuniformities. The neutron-production rate for these thick shells truncates relative to one-dimensional (1-D) predictions. The yield degradation in the thin shells is mainly due to shell breakup at short wavelengths ({lambda} {approx} {Delta}, where {Delta} is the in-flight shell thickness). The neutron-rate curves for the thinner shells have significantly lower amplitudes and a fall-off that is less steep than 1-D rates. DRACO simulation results are consistent with experimental observations
- β¦